Osteoporosis and Risk of Hearing Loss: Protective Effects of Zoledronic Acid and Denosumab in a Nationwide Cohort
Journal of the American Geriatrics Society · 2026-10 · 74 (10) · 2989-2996
DOI: 10.1111/jgs.70654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, online erschienen am 10.08.2026. Verfasst von Shih-Han Hung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Osteoporosis, Denosumab, Bone Density Conservation Agents, Zoledronic Acid. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Osteoporosis and fragility fractures may be associated with hearing loss, but whether osteoporosis treatments influence this risk remains unclear.
Design
Retrospective cohort study.
Setting
Taiwan's National Health Insurance Research Database (2011–2017).
Participants
For Objective 1, adults aged 65 years and older with osteoporosis or fragility fractures ( n = 331,867) and matched controls ( n = 331,867); for Objective 2, patients with osteoporosis or fragility fractures treated with zoledronic acid ( n = 21,811), treated with denosumab ( n = 21,811), or without treatment ( n = 21,811).
Measurements
The primary outcome was incident hearing loss. Propensity score matching (1:1 or 1:1:1) was performed using age, sex, and Charlson Comorbidity Index covariates. Hazard ratios (HRs) were estimated using Cox proportional hazards models adjusted for comorbidities.
Results
Patients with osteoporosis or fragility fractures showed a significantly higher incidence of hearing loss than controls (adjusted HR: 1.34, 95% CI: 1.31–1.37, p < 0.001). Among affected individuals, those treated with zoledronic acid (HR: 0.87, 95% CI: 0.81–0.93) or denosumab (HR: 0.91, 95% CI: 0.85–0.97) had a significantly lower risk of hearing loss than untreated patients. Zoledronic acid reduced the risk of hearing loss in both sexes, whereas the association of denosumab with reduced risk was statistically significant only in male patients.
Conclusion
Osteoporosis and fragility fractures are associated with an increased risk of hearing loss. Treatment with zoledronic acid was associated with a reduced risk of hearing loss in both sexes, whereas denosumab was associated with such a reduction only in male patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Department of Otolaryngology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
- School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
- Department of Family Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Leisure Services Management, Chaoyang University of Technology, Taichung, Taiwan.
- International PhD Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan.
ORCID-Profile: Wing P Chan
Zitieren
APA
Hung, S. H., Huang, C. F., Hsu, J. C., Carey, J. J., Griffith, J. F., & Chan, W. P. (2026). Osteoporosis and Risk of Hearing Loss: Protective Effects of Zoledronic Acid and Denosumab in a Nationwide Cohort. Journal of the American Geriatrics Society, 74(10), 2989-2996. https://doi.org/10.1111/jgs.70654
Vancouver
Hung SH, Huang CF, Hsu JC, Carey JJ, Griffith JF, Chan WP. Osteoporosis and Risk of Hearing Loss: Protective Effects of Zoledronic Acid and Denosumab in a Nationwide Cohort. Journal of the American Geriatrics Society. 2026;74(10):2989-2996. doi:10.1111/jgs.70654
BibTeX
@article{Hung2026,
author = {Hung, Shih-Han and Huang, Chun-Feng and Hsu, Jason C and Carey, John J and Griffith, James F and Chan, Wing P},
title = {Osteoporosis and Risk of Hearing Loss: Protective Effects of Zoledronic Acid and Denosumab in a Nationwide Cohort},
journal = {Journal of the American Geriatrics Society},
year = {2026},
volume = {74},
number = {10},
pages = {2989--2996},
doi = {10.1111/jgs.70654}
}
EUVIMED